KDKarin Dijkman

Karin Dijkman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karin Dijkman has a total of 168 co-authors. Here are the top co-authors by number of shared publications:

  • Annemieke Geluk

    Leiden University Center of Infectious Diseases (LUCID), Leiden University Medical Center (LUMC), the Netherlands

    6 shared publications
  • Tom H. M. Ottenhoff

    The department of Infectious Diseases, Leiden University Medical Centre (LUMC), Leiden, the Netherlands

    6 shared publications
  • Krista E. van Meijgaarden

    Department of Infectious Diseases, Leiden University Medical Centre, Leiden, Netherlands

    5 shared publications
  • Louis Wilson

    Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

    5 shared publications
  • Charelle Boot

    Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands

    4 shared publications
  • Kees L. M. C. Franken

    Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Complement in tuberculosis infection and disease, a battle of two ancients

    by Karin Dijkman, Simone A. Joosten, Leendert A. Trouw


  • Open Access

    Ad26.RSV.preF completely protects calves from severe respiratory disease induced by bovine RSV challenge

    by Leslie van der Fits, Rineke de Jong, Karin Dijkman, Marjolein Heemskerk-Van der Meer, Lisanne Tettero, Judith Bonsing, Sophie van Oort, Jan Serroyen, Marianke van Schie, Norbert Stockhofe-Zurwieden, et al.

    Vaccination with Ad26.RSV.preF, an Adenoviral serotype 26 vector encoding RSV F protein stabilized in its prefusion conformation, has previously shown to be immunogenic and protective in RSV seropositive adults and immunogenic in seropositive infants. Human and bovine RSV (bRSV) are genetically highly related and share many aspects of pathogenesis, epidemiology and clinical manifestations at young age. As such, infection of calves with bRSV represents a clinically relevant model with high translational value, enabling preclinical evaluation of Ad26.RSV.preF vaccine efficacy in seronegative young animals. Immunization of young calves with Ad26.RSV.preF induced antibodies neutralizing both human and bovine RSV as well as RSV-specific cellular responses. After bRSV challenge, placebo immunized calves showed viral replication in the respiratory tract, and developed fever and lethargy accompanied with severe respiratory distress, resulting in pre-termination of 7/8 calves. In contrast, all Ad26.RSV.preF immunized calves completed the study with only mild clinical symptoms, strongly and significantly diminished viral loads in nasopharynx and lungs, and only minimal lung pathology. Thus, Ad26.RSV.preF is immunogenic in young calves and efficacious in a stringent heterologous bRSV challenge model, demonstrating induction of broadly protective immunity against severe disease.


  • Top Cited Papers
    Open Access

    A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

    by Joshua S. Woodworth, Helena Strand Clemmensen, Hannah Battey, Karin Dijkman, Thomas Lindenstrøm, Raquel Salvador Laureano, Randy Taplitz, Jeffrey Morgan, Claus Aagaard, Ida Rosenkrands, et al.

    Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Guérin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and Mycobacterium tuberculosis (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG + subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces ‘adjuvant-imprinted’ qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.


  • Open Access

    Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections

    by Mt Heemskerk, Cj Korbee, J Esselink, C Carvalho dos Santos, S van Veen, If Gordijn, F Vrieling, Kv Walburg, Cg Engele, K Dijkman, et al.

    The persistent increase of multidrug-resistant (MDR) Mycobacterium tuberculosis ( Mtb ) infections negatively impacts Tuberculosis (TB) treatment outcomes. Host-directed therapies (HDT) pose an complementing strategy, particularly since Mtb is highly successful in evading host-defense by manipulating host-signaling pathways. Here, we screened a library containing autophagy-modulating compounds for their ability to inhibit intracellular Mtb -bacteria. Several active compounds were identified, including two drugs of the diphenylbutylpiperidine-class, Fluspirilene and Pimozide, commonly used as antipsychotics. Both molecules inhibited intracellular Mtb in pro- as well as anti-inflammatory primary human macrophages in a host-directed manner and synergized with conventional anti-bacterials. Importantly, these inhibitory effects extended to MDR- Mtb strains and the unrelated intracellular pathogen, Salmonella enterica serovar Typhimurium ( Stm ). Mechanistically Fluspirilene and Pimozide were shown to regulate autophagy and alter the lysosomal response, partly correlating with increased bacterial localization to autophago(lyso)somes. Pimozide’s and Fluspirilene’s efficacy was inhibited by antioxidants, suggesting involvement of the oxidative-stress response in Mtb growth control. Furthermore, Fluspirilene and especially Pimozide counteracted Mtb -induced STAT5 phosphorylation, thereby reducing Mtb phagosome-localized CISH that promotes phagosomal acidification. In conclusion, two approved antipsychotic drugs, Pimozide and Fluspirilene, constitute highly promising and rapidly translatable candidates for HDT against Mtb and Stm and act by modulating the autophagic/lysosomal response by multiple mechanisms.


  • Open Access

    A novel Mycobacterium tuberculosis-specific subunit vaccine provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin

    by Joshua S. Woodworth, Helena Strand Clemmensen, Hannah Battey, Karin Dijkman, Thomas Lindenstrøm, Raquel Salvador Laureano, Randy Taplitz, Jeffrey Morgan, Claus Aagaard, Ida Rosenkrands, et al.

    Tuberculosis (TB) remains a global health crisis. Following encouraging clinical results of subunit vaccination and revaccination with Bacillus Calmette-Guérin (BCG), it has been suggested to combine BCG and subunit vaccines for increased efficacy. Current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study was to design a subunit vaccine that does not share antigens with BCG and explore the advantages of a BCG+subunit vaccine co-administration strategy, where the two vaccines do not cross-react. Eight protective antigens were selected to create a Mycobacterium tuberculosis (Mtb)-specific subunit vaccine, named H107. Whereas subunit vaccines with BCG-shared antigens displayed cross-reactivity to BCG in vivo in both mice and humans, H107 showed no cross-reactivity and did not inhibit BCG colonization in mice. Encouragingly, co-administering H107 with BCG (BCG+H107) led to increased adaptive immune responses against both H107 and BCG leading to improved BCG-mediated immunity. In contrast to subunit vaccines with BCG-shared antigens, ‘boosting’ BCG with H107 led to substantial expansion of clonal diversity in the T cell repertoire, and BCG+H107 co-administration conferred significantly increased Th17 responses and less differentiated CD4 T cells. CD4 T cells induced by BCG+H107 maintained functional superiority after Mtb infection, and BCG+H107 provided significantly increased long-term protection compared to both BCG and H107 alone, as well as, BCG co-administered with a subunit vaccine composed of antigens shared with BCG. Overall, we identify several advantages of combining an Mtb-specific subunit vaccine with BCG and introduce H107 as a BCG-complementing vaccine with distinctive value for co-administration with BCG.


  • Open Access

    Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection

    by Karin Dijkman, Nacho Aguilo, Charelle Boot, Sam O. Hofman, Claudia C. Sombroek, Richard A.W. Vervenne, Clemens H.M. Kocken, Dessislava Marinova, Jelle Thole, Esteban Rodríguez, et al.


  • Open Access

    Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques

    by Michel P. M. Vierboom, Agnes L. Chenine, Patricia A. Darrah, Richard A. W. Vervenne, Charelle Boot, Sam O. Hofman, Claudia C. Sombroek, Karin Dijkman, Mohamed A. Khayum, Marieke A. Stammes, et al.

    Tuberculosis (TB) still is the principal cause of death from infectious disease and improved vaccination strategies are required to reduce the disease burden and break TB transmission. Here, we investigated different routes of administration of vectored subunit vaccines based on chimpanzee-derived adenovirus serotype-3 (ChAd3) for homologous prime-boosting and modified vaccinia virus Ankara (MVA) for heterologous boosting with both vaccine vectors expressing the same antigens from Mycobacterium tuberculosis (Ag85B, ESAT6, Rv2626, Rv1733, RpfD). Prime-boost strategies were evaluated for immunogenicity and protective efficacy in highly susceptible rhesus macaques. A fully parenteral administration regimen was compared to exclusive respiratory mucosal administration, while parenteral ChAd3-5Ag prime-boosting and mucosal MVA-5Ag boosting were applied as a push-and-pull strategy from the periphery to the lung. Immune analyses corroborated compartmentalized responses induced by parenteral versus mucosal vaccination. Despite eliciting TB-specific immune responses, none of the investigational regimes conferred a protective effect by standard readouts of TB compared to non-vaccinated controls, while lack of protection by BCG underpinned the stringency of this non-human primate test modality. Yet, TB manifestation after full parenteral vaccination was significantly less compared to exclusive mucosal vaccination.


  • Open Access

    Systemic and pulmonary C1q as biomarker of progressive disease in experimental non-human primate tuberculosis

    by Karin Dijkman, Rosalie Lubbers, Nicole V. Borggreven, Tom H. M. Ottenhoff, Simone A. Joosten, Leendert A. Trouw, Frank A. W. Verreck

    Tuberculosis (TB) causes 1.6 million deaths annually. Early differential diagnosis of active TB infection is essential in optimizing treatment and reducing TB mortality, but is hampered by a lack of accurate and accessible diagnostics. Previously, we reported on complement component C1q, measured in serum by ELISA, as a candidate biomarker for active tuberculosis. In this work we further examine the dynamics of C1q as a marker of progressive TB disease in non-human primates (NHP). We assessed systemic and pulmonary C1q levels after experimental infection using high or low single dose as well as repeated limiting dose Mycobacterium tuberculosis (Mtb) challenge of macaques. We show that increasing C1q levels, either peripherally or locally, correlate with progressive TB disease, assessed by PET-CT imaging or post-mortem evaluation. Upregulation of C1q did not precede detection of Mtb infection by a conventional interferon-gamma release assay, confirming its association with disease progression. Finally, pulmonary vaccination with Bacillus Calmette Guérin also increased local production of C1q, which might contribute to the generation of pulmonary protective immunity. Our data demonstrate that NHP modelling of TB can be utilized to study the role of C1q as a liquid biomarker in TB protection and disease, complementing findings in TB patients.


  • Open Access

    Disparate Tuberculosis Disease Development in Macaque Species Is Associated With Innate Immunity

    by Karin Dijkman, Richard A. W. Vervenne, Claudia C. Sombroek, Charelle Boot, Sam O. Hofman, Krista E. van Meijgaarden, Tom H. M. Ottenhoff, Clemens H. M. Kocken, Krista G. Haanstra, Michel P. M. Vierboom, et al.

    While tuberculosis continues to afflict mankind, the immunological mechanisms underlying TB disease development are still incompletely understood. Advanced preclinical models for TB research include both rhesus and cynomolgus macaques (Macaca mulatta and Macaca fascicularis, respectively), with rhesus typically being more susceptible to acute progressive TB disease than cynomolgus macaques. To determine which immune mechanisms are responsible for this dissimilar disease development, we profiled a broad range of innate and adaptive responses, both local and peripheral, following experimental pulmonary Mycobacterium tuberculosis (Mtb) infection of both species. While T-cell and antibody responses appeared indistinguishable, we identified anti-inflammatory skewing of peripheral monocytes in rhesus and a more prominent local pro-inflammatory cytokine release profile in cynomolgus macaques associated with divergent TB disease outcome. Importantly, these differences were detectable both before and early after infection. This work shows that inflammatory and innate immune status prior to and at early stages after infection, critically affects outcome of TB infection.